Supriya Lifescience Ltd., a leading cGMP-compliant API manufacturer, has reinforced its commitment to sustainability with the inauguration of a state-of-the-art 5 MWp solar power facility in Nanded District, Maharashtra. The project was inaugurated by Dr. Satish Wagh, Chairman of Supriya Lifescience, who highlighted the company’s dedication to renewable energy and environmental responsibility.
This initiative is part of Supriya Lifescience’s ongoing efforts to reduce its carbon footprint. With the addition of the Nanded facility, the company’s total installed solar capacity now stands at 9.85 MWp, up from 4.85 MWp across existing solar projects in Solapur District, Maharashtra. These renewable energy projects significantly reduce reliance on fossil fuels and contribute to India’s broader climate change objectives by fostering a cleaner and more sustainable energy ecosystem.
“Embracing renewable energy is not just a strategic business decision but also a commitment to a greener future,” said Dr. Satish Wagh, Chairman and Whole-Time Director, Supriya Lifescience Ltd. “Our investments in solar power are integral to our vision of sustainable growth and reducing environmental impact.”
The latest solar project was executed in collaboration with Enrich Energy Pvt. Ltd., a leading renewable energy solutions provider. By integrating solar energy into its operations, Supriya Lifescience demonstrates its commitment to green manufacturing and proactive energy efficiency in the pharmaceutical sector.
As a key player in the pharmaceutical industry, Supriya Lifescience continues to lead sustainability efforts by aligning its operations with global best practices in energy conservation. Through solar energy adoption, the company contributes to India’s renewable energy goals while reducing greenhouse gas emissions, reinforcing its position as a responsible corporate entity.
About Supriya Lifescience Ltd.
Founded in 1987, Supriya Lifescience Ltd. is a globally recognized manufacturer of active pharmaceutical ingredients (APIs). The company’s cutting-edge facility is accredited by Health Canada, EUGMP, EDQM, USFDA, and NMPA, ensuring adherence to the highest quality standards. Headquartered in Mumbai, India, with its production facility in Khed, District Ratnagiri, Supriya Lifescience maintains globally compliant facilities approved by EMA, US FDA, WHO, PMDA, TGA, KFDA, and ANVISA.
Supported by robust R&D, the company boasts eight active CEPs and fourteen active USDMFs, adhering to stringent EHS (Environmental, Health, and Safety) requirements and ethical business practices. Supriya Lifescience focuses on manufacturing intermediates and APIs for both innovators and generic pharmaceutical firms while also offering exclusive partnerships as a Contract Manufacturing Organization (CMO).
